The top vaccine official with the Food and Drug Administration has resigned and criticized the nation's top health official for allowing “misinformation and lies” to guide his thinking behind the safety of vaccinations.

Robert F.

Food and Drug Administration nominee Dr. Marty Makary is known for his contrarian views and fiery criticism of traditional medical institutions.

Newly installed Health and Human Services Secretary Robert F.

The U.S. is poised to make COVID-19 vaccinations more like a yearly flu shot.

The U.S. is poised to make COVID-19 vaccinations more like a yearly flu shot, a major shift in strategy despite a long list of questions about how to best protect against a still rapidly mutating virus.

A federally funded study has found a possible link between aluminum in some childhood vaccines and persistent asthma, but experts say the study has several shortcomings.

A new government report shows Pfizer’s COVID-19 vaccine gave children 5 and older strong protection against hospitalization and death even during the omicron surge.

The omicron-fueled surge that is sending COVID-19 cases rocketing in the U.S. is putting children in the hospital in record numbers.

A panel of U.S. health advisers has endorsed booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine.

An influential federal advisory panel has overwhelmingly rejected a plan to give Pfizer booster shots against COVID-19 to most Americans, but it endorsed the extra doses for those who are 65 or older or run a high risk of severe disease.

President Joe Biden’s administration drew up a strategy to contain one coronavirus strain, then another showed up that’s much more contagious.

An advisory committee for the Food and Drug Administration is convening Thursday morning to discuss what data the agency would need in order to consider the potential use of the COVID-19 vaccine on children younger than 12.

The world’s leading COVID-19 vaccines may offer lasting protection that diminishes the need for frequent booster shots.

State data shows over 20,000 young teens have been vaccinated in Florida as eligibility expanded to children as young as 12 nearly one week ago.

Public health experts say there has been some hesitancy among parents to have their child receive a COVID-19 vaccine.

WASHINGTON – U.S. health advisers endorsed a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, putting the nation on the cusp of adding an easier-to-use option to fight the pandemic. One challenge in rolling out the new vaccine will be explaining how protective the J&J shot is after the astounding success of the first U.S. vaccines. One dose of the J&J vaccine was 85% protective against the most severe COVID-19. AdImportantly, the FDA reported this week that, just like its predecessors, the J&J shot offers strong protection against the worst outcomes, hospitalization and death. On Sunday, a CDC panel is expected to meet to recommend how to best prioritize use of the J&J vaccine.

AdTests showed the Pfizer and Moderna vaccines were 95% effective at protection against symptomatic COVID-19. Across all countries, the analysis of the J&J vaccine showed protection began to emerge about 14 days after vaccination. All of the world’s COVID-19 vaccines have been tested differently, making comparisons nearly impossible. Like other COVID-19 vaccines, the main side effects of the J&J shot are pain at the injection site and flu-like fever, fatigue and headache. AdIf the FDA clears the J&J shot for U.S. use, it will not boost vaccine supplies significantly right away.

Trucks will roll out Sunday morning as shipping companies UPS and FedEx begin delivering Pfizer’s vaccine to nearly 150 distribution centers across the states, said Army Gen. Gustave Perna of Operation Warp Speed, the Trump administration’s vaccine development program. Initially, about 3 million doses were expected to be shipped nationwide. Perna compared the vaccine distribution effort to D-Day, the U.S.-led military offensive that turned the tide in World War II. The vaccine was timed to arrive Monday so health workers could receive the shots and begin giving them, Perna said. The announcement came after revelations that the White House opted not to lock in an additional 100 million doses of Pfizer’s vaccine for delivery in the second quarter of 2021.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. Next week, the FDA will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. As a result, the expert panel wrestled with a list of questions that have yet to be answered. The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

University of Hong Kong scientists claim to have the first evidence of someone being reinfected with the virus that causes COVID-19. The man had mild symptoms the first time and none the second time; his more recent infection was detected through screening and testing at the Hong Kong airport. It shows that some people do not have lifelong immunity to the virus if they've already had it, To said. If there is a reinfection, it suggests the possibility there was residual immunity ... that helped protect the patient from getting sick again, Goodman said. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education.